CEP19

Summary

CEP19 (centrosomal protein 19, HGNC:28209) is a protein-coding gene on chromosome 3q29, encoding Centrosomal protein of 19 kDa (Q96LK0). Required for ciliation.

The protein encoded by this gene localizes to centrosomes and primary cilia and co-localizes with a marker for the mother centriole. This gene resides in a region of human chromosome 3 that is linked to morbid obesity. A homozygous knockout of the orthologous gene in mouse resulted in mice with morbid obesity, hyperphagy, glucose intolerance, and insulin resistance. Mutations in this gene cause morbid obesity and spermatogenic failure (MOSPGF). This gene has a pseudogene on human chromosome 2.

Source: NCBI Gene 84984 — RefSeq curated summary.

At a glance

• Gene–disease (curated): obesity due to CEP19 deficiency (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 4
• Clinical variants (ClinVar): 131 total — 8 pathogenic
• Phenotypes (HPO): 103
• MANE Select transcript: NM_032898

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28209
Approved symbol	CEP19
Name	centrosomal protein 19
Location	3q29
Locus type	gene with protein product
Status	Approved
Aliases	MGC14126
Ensembl gene	ENSG00000174007
Ensembl biotype	protein_coding
OMIM	615586
Entrez	84984

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 13 protein_coding

ENST00000399942, ENST00000409690, ENST00000893283, ENST00000893284, ENST00000893285, ENST00000893286, ENST00000933600, ENST00000933601, ENST00000959538, ENST00000959539, ENST00000959540, ENST00000959541, ENST00000959542

RefSeq mRNA: 4 — MANE Select: NM_032898 NM_001379468, NM_001379469, NM_001379470, NM_032898

CCDS: CCDS43193, CCDS93445

Canonical transcript exons

ENST00000409690 — 3 exons

Exon	Start	End
ENSE00001189550	196708528	196708727
ENSE00001577166	196706277	196707912
ENSE00001903592	196711929	196712250

Expression profiles

Bgee: expression breadth ubiquitous, 214 present calls, max score 87.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.7879 / max 86.7396, expressed in 1431 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
46382	3.5305	1413
46381	0.1727	48
46380	0.0847	33

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.95	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.31	gold quality
blood	UBERON:0000178	84.77	gold quality
oviduct epithelium	UBERON:0004804	83.12	gold quality
middle temporal gyrus	UBERON:0002771	82.85	gold quality
bronchial epithelial cell	CL:0002328	82.17	gold quality
sperm	CL:0000019	81.95	gold quality
bronchus	UBERON:0002185	80.95	gold quality
secondary oocyte	CL:0000655	80.67	gold quality
cortical plate	UBERON:0005343	80.62	gold quality
Brodmann (1909) area 23	UBERON:0013554	79.02	gold quality
mucosa of paranasal sinus	UBERON:0005030	78.52	gold quality
postcentral gyrus	UBERON:0002581	77.70	gold quality
superior frontal gyrus	UBERON:0002661	77.62	gold quality
prefrontal cortex	UBERON:0000451	77.36	gold quality
epithelium of nasopharynx	UBERON:0001951	77.00	gold quality
entorhinal cortex	UBERON:0002728	76.70	gold quality
primary visual cortex	UBERON:0002436	76.68	gold quality
frontal cortex	UBERON:0001870	76.13	gold quality
neocortex	UBERON:0001950	76.02	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	75.90	gold quality
testis	UBERON:0000473	75.88	gold quality
Brodmann (1909) area 9	UBERON:0013540	75.49	gold quality
cerebral cortex	UBERON:0000956	75.47	gold quality
buccal mucosa cell	CL:0002336	75.26	silver quality
ventricular zone	UBERON:0003053	75.18	gold quality
anterior cingulate cortex	UBERON:0009835	75.11	gold quality
trabecular bone tissue	UBERON:0002483	74.68	gold quality
right frontal lobe	UBERON:0002810	74.61	gold quality
right testis	UBERON:0004534	74.43	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6142	no	106.07
E-ANND-3	no	2.66

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

74 targeting CEP19, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488

Literature-anchored findings (GeneRIF, showing 4)

• loss of the ciliary protein CEP19 in humans and mice causes morbid obesity. (PMID:24268657)
• RABL2 binds to CEP19 and the IFT74-IFT81 heterodimer in a mutually exclusive manner. (PMID:28428259)
• CEP19 is recruited to the ciliary base by the centriolar CEP350/FOP complex and then specifically captures GTP-bound RABL2B, which is activated via its intrinsic nucleotide exchange. (PMID:28625565)
• CEP19 encodes a centrosomal and ciliary protein, as all BBS genes do. Another truncating mutation p.Arg82* has been reported as responsible for morbid obesity in a family; however, in the family we present, not all homozygotes are obese, although some are severely obese. (PMID:29127258)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cep19	ENSDARG00000059175
mus_musculus	Cep19	ENSMUSG00000035790
rattus_norvegicus	Cep19	ENSRNOG00000024924

Protein

Protein identifiers

Centrosomal protein of 19 kDa — Q96LK0 (reviewed: Q96LK0)

All UniProt accessions (2): Q96LK0, A8MX07

UniProt curated annotations — full annotation on UniProt →

Function. Required for ciliation. Recruits the RABL2B GTPase to the ciliary base to initiate ciliation. After specifically capturing the activated GTP-bound RABL2B, the CEP19-RABL2B complex binds intraflagellar transport (IFT) complex B from the large pool pre-docked at the base of the cilium and thus triggers its entry into the cilia. Involved in the early steps in cilia formation by recruiting the ciliary vesicles (CVs) to the distal end of the mother centriole where they fuse to initiate cilium assembly. Involved in microtubule (MT) anchoring to the centrosomes.

Subunit / interactions. Interacts with CEP43; this interaction is required for its localization to the mother centriole. Interacts (via residues 121-150) with RABL2B. Interacts (via C-terminus) with CEP350; this interaction is required for its localization to the mother centriole.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Centriole. Spindle pole. Cilium basal body.

Disease relevance. Morbid obesity and spermatogenic failure (MOSPGF) [MIM:615703] An autosomal recessive morbid obesity syndrome characterized by hypertension, fatty liver disease, insulin resistance, and decreased sperm counts. Variable clinical manifestations are early coronary artery disease with myocardial infarction before 45 years of age, type II diabetes mellitus, and intellectual disability. Morbid obese individuals are defined as having a BMI greater than 40. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the CEP19 family.

RefSeq proteins (4): NP_001366397, NP_001366398, NP_001366399, NP_116287* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029412	CEP19	Family

Pfam: PF14933

UniProt features (1 total): chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96LK0-F1	82.85	0.31

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 341 (showing top): GOBP_VESICLE_LOCALIZATION, GOBP_MICROTUBULE_ANCHORING, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_VESICLE_TARGETING, GOBP_VESICLE_MEDIATED_TRANSPORT, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_CILIUM_ORGANIZATION, GOCC_CENTROSOME, GOBP_ORGANELLE_ASSEMBLY, GOBP_CELL_PROJECTION_ORGANIZATION, GOBP_ORGANELLE_LOCALIZATION, GOCC_SPINDLE, GOCC_CENTRIOLE, GOCC_CILIUM, GOCC_CILIARY_BASAL_BODY

GO Biological Process (4): microtubule anchoring at centrosome (GO:0034454), cilium assembly (GO:0060271), trans-Golgi to periciliary membrane compartment transport (GO:0097712), cell projection organization (GO:0030030)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (10): spindle pole (GO:0000922), nucleoplasm (GO:0005654), centrosome (GO:0005813), centriole (GO:0005814), cytosol (GO:0005829), cilium (GO:0005929), ciliary basal body (GO:0036064), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
microtubule organizing center	3
intracellular membraneless organelle	2
microtubule anchoring at microtubule organizing center	1
axoneme assembly	1
intraciliary transport involved in cilium assembly	1
cilium organization	1
protein localization to cilium	1
organelle assembly	1
trans-Golgi to periciliary membrane compartment transport	1
plasma membrane bounded cell projection assembly	1
ciliary transition zone assembly	1
Golgi to plasma membrane transport	1
cilium assembly	1
cellular component organization	1
binding	1
spindle	1
nuclear lumen	1
centriole	1
cytoplasm	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
cilium	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

646 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CEP19	RABL2A	Q9UBK7	809
CEP19	CEP43	O95684	730
CEP19	CEP350	Q5VT06	693
CEP19	RABL2B	Q9UNT1	659
CEP19	CEP89	Q96ST8	646
CEP19	SMCO1	Q147U7	634
CEP19	SCLT1	Q96NL6	594
CEP19	UBXN7	O94888	591
CEP19	WDR53	Q7Z5U6	583
CEP19	DYNLT2B	Q8WW35	580
CEP19	CEP20	Q96NB1	577
CEP19	CEP164	Q9UPV0	531
CEP19	CEP128	Q6ZU80	528
CEP19	ZDHHC19	Q8WVZ1	522
CEP19	ARL13B	Q3SXY8	516

IntAct

203 interactions, top by confidence:

A	B	Type	Score
KXD1	CEP19	psi-mi:“MI:0915”(physical association)	0.780
CEP19	KXD1	psi-mi:“MI:0915”(physical association)	0.780
CEP43	CEP19	psi-mi:“MI:0915”(physical association)	0.770
CEP19	CEP43	psi-mi:“MI:0915”(physical association)	0.770
CEP19	CEP43	psi-mi:“MI:0914”(association)	0.770
CCDC102B	CEP19	psi-mi:“MI:0915”(physical association)	0.720
CEP19	ZBTB14	psi-mi:“MI:0915”(physical association)	0.720
CALCOCO1	CEP19	psi-mi:“MI:0915”(physical association)	0.720
CEP19	RABL2A	psi-mi:“MI:0915”(physical association)	0.720
VCP	CEP19	psi-mi:“MI:0915”(physical association)	0.720
CEP19	CCDC102B	psi-mi:“MI:0915”(physical association)	0.720
ZBTB14	CEP19	psi-mi:“MI:0915”(physical association)	0.720
CEP19	CALCOCO1	psi-mi:“MI:0915”(physical association)	0.720
CEP19	VCP	psi-mi:“MI:0915”(physical association)	0.720
PIK3R3	CEP19	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (188): CEP19 (Two-hybrid), CEP19 (Two-hybrid), CEP19 (Two-hybrid), CEP19 (Two-hybrid), CEP19 (Two-hybrid), CEP19 (Two-hybrid), CEP19 (Two-hybrid), CEP19 (Two-hybrid), KIAA1958 (Two-hybrid), SYNE4 (Two-hybrid), CEP19 (Affinity Capture-MS), CEP19 (Two-hybrid), CEP19 (Two-hybrid), CEP19 (Two-hybrid), FGFR1OP (Affinity Capture-Western)

ESM2 similar proteins: A0A1L8H579, A0A1L8HCK2, A1CMP1, A1DL98, A1L3H4, A2R091, A5DQ88, A5PN52, A6H7C9, A6S6B0, A7F9B8, A7S7F2, A9UL78, A9ULR1, O04438, O59731, P20147, P20290, P33716, P34316, P51406, P57076, Q02106, Q02872, Q0ULD0, Q10209, Q1DI23, Q21920, Q2NL37, Q3M6B5, Q58FF3, Q5ASI4, Q5U3Z0, Q64152, Q6DRC3, Q6T938, Q8BL95, Q8GX05, Q8N8J0, Q8RWS4

Diamond homologs: A6H7C9, A9UL78, Q4V8Z3, Q96LK0, Q9CQA8, Q9QZX9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

131 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	8
Likely pathogenic	0
Uncertain significance	83
Likely benign	29
Benign	5

Top pathogenic / likely-pathogenic (8)

Variant ID	HGVS	Classification
1340723	GRCh37/hg19 3q29(chr3:195914129-196804639)x1	Pathogenic
1679598	Single allele	Pathogenic
430642	NM_032898.5(CEP19):c.182dup (p.Tyr61Ter)	Pathogenic
545295	NC_000003.12:g.(?196154147)(197376501_?)del	Pathogenic
562866	GRCh37/hg19 3q29(chr3:195725290-197015654)x1	Pathogenic
57328	GRCh38/hg38 3q29(chr3:196013486-197503306)x3	Pathogenic
57492	GRCh38/hg38 3q29(chr3:196077857-197165715)x1	Pathogenic
997056	GRCh37/hg19 3q29(chr3:195419168-197387258)	Pathogenic

SpliceAI

503 predictions. Top by Δscore:

Variant	Effect	Δscore
3:196707909:CAAT:C	acceptor_gain	1.0000
3:196707910:AATC:A	acceptor_loss	1.0000
3:196707913:C:CA	acceptor_loss	1.0000
3:196707913:C:CC	acceptor_gain	1.0000
3:196707908:GCAAT:G	acceptor_gain	0.9900
3:196707909:CAATC:C	acceptor_gain	0.9900
3:196707910:AAT:A	acceptor_gain	0.9900
3:196707911:AT:A	acceptor_gain	0.9900
3:196707911:ATCT:A	acceptor_gain	0.9800
3:196712110:C:CA	donor_gain	0.9800
3:196712111:C:A	donor_gain	0.9800
3:196707910:AATCT:A	acceptor_gain	0.9700
3:196708728:C:CC	acceptor_gain	0.9700
3:196707912:TCT:T	acceptor_gain	0.9600
3:196708415:A:AC	donor_gain	0.9600
3:196708416:C:CC	donor_gain	0.9600
3:196708523:GGTA:G	donor_loss	0.9600
3:196708524:GTACC:G	donor_loss	0.9600
3:196708525:TA:T	donor_loss	0.9600
3:196708526:A:AT	donor_loss	0.9600
3:196708527:CCTG:C	donor_loss	0.9600
3:196708529:TGAAA:T	donor_gain	0.9600
3:196711927:AC:A	donor_gain	0.9600
3:196711928:CC:C	donor_gain	0.9600
3:196708528:C:G	donor_loss	0.9500
3:196708725:CTG:C	acceptor_gain	0.9500
3:196712086:A:AC	donor_gain	0.9500
3:196712087:C:CC	donor_gain	0.9500
3:196708721:CTTC:C	acceptor_gain	0.9400
3:196708723:TCCTG:T	acceptor_loss	0.9400

AlphaMissense

1119 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000373958 (3:196711475 A>G), RS1001543566 (3:196711841 C>T), RS1001818922 (3:196706426 G>T), RS1002102030 (3:196710767 A>C), RS1002169962 (3:196712063 G>C,T), RS1002320663 (3:196710864 A>C), RS1002559162 (3:196711144 T>G), RS1002926723 (3:196713171 C>T), RS1003598054 (3:196707273 C>T), RS1003853643 (3:196713407 A>G), RS1004115393 (3:196707036 T>C,G), RS1004609734 (3:196711739 G>C), RS1004852553 (3:196706111 T>C), RS1005275470 (3:196713861 G>A,T), RS1006139995 (3:196714095 CTAATT>C)

Disease associations

OMIM: gene MIM:615586 | disease phenotypes: MIM:615703, MIM:609425, MIM:209900, MIM:181500

GenCC curated gene-disease

Disease	Classification	Inheritance
obesity due to CEP19 deficiency	Strong	Autosomal recessive
Bardet-Biedl syndrome	Supportive	Autosomal recessive

Mondo (5): optic atrophy (MONDO:0003608), obesity due to CEP19 deficiency (MONDO:0014309), chromosome 3q29 microdeletion syndrome (MONDO:0012269), Bardet-Biedl syndrome (MONDO:0015229), schizophrenia (MONDO:0005090)

Orphanet (4): Obesity due to CEP19 deficiency (Orphanet:397615), 3q29 microdeletion syndrome (Orphanet:65286), Bardet-Biedl syndrome (Orphanet:110), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

103 total (30 of 103 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000011	Neurogenic bladder
HP:0000027	Azoospermia
HP:0000028	Cryptorchidism
HP:0000076	Vesicoureteral reflux
HP:0000085	Horseshoe kidney
HP:0000100	Nephrotic syndrome
HP:0000119	Abnormality of the genitourinary system
HP:0000126	Hydronephrosis
HP:0000135	Hypogonadism
HP:0000147	Polycystic ovaries
HP:0000163	Abnormal oral cavity morphology
HP:0000218	High palate
HP:0000278	Retrognathia
HP:0000316	Hypertelorism
HP:0000343	Long philtrum
HP:0000358	Posteriorly rotated ears
HP:0000365	Hearing impairment
HP:0000388	Otitis media
HP:0000400	Macrotia
HP:0000426	Prominent nasal bridge
HP:0000470	Short neck
HP:0000483	Astigmatism
HP:0000486	Strabismus
HP:0000494	Downslanted palpebral fissures
HP:0000512	Abnormal electroretinogram
HP:0000518	Cataract
HP:0000548	Cone/cone-rod dystrophy
HP:0000551	Color vision defect
HP:0000556	Retinal dystrophy

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST005038_10	Allergic disease (asthma, hay fever or eczema)	2.000000e-12
GCST007798_62	Asthma	9.000000e-13
GCST009391_625	Metabolite levels	1.000000e-06
GCST009798_34	Asthma	4.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010506	kynurenic acid measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D020788	Bardet-Biedl Syndrome	C10.228.140.617.200; C11.270.684.624; C16.131.077.245.125; C16.320.184.125
D009896	Optic Atrophy	C10.292.700.225; C11.640.451
C567184	Chromosome 3q29 Deletion Syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	5
Benzo(a)pyrene	decreases expression, increases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Particulate Matter	affects cotreatment, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
urushiol	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
(+)-JQ1 compound	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Glyphosate	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Cisplatin	increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Ethyl Methanesulfonate	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety